ChronoScale Reports Fiscal First Quarter 2027 Results

ChronoScale Holdings reported fiscal first quarter 2027 results for the period ended Aug. 31, 2026. Revenue was $41.5 million, up 148% from $16.7 million a year earlier. The company posted a net loss of $26.4 million, or $0.18 per basic and diluted share, and adjusted EBITDA of $5.9 million. Following its May 5, 2026 business combination, the legacy Ekso Bionics business was classified as held for sale and its results are presented as discontinued operations; the sale was completed Sept. 30, 2026. Operationally, ChronoScale secured a 50 MW AI compute deployment with Microsoft that will integrate NVIDIA GB300 NVL72 systems with liquid cooling and purpose-built infrastructure. It also entered strategic partnerships with Nutanix and a three-year agreement with Baseten Labs to support ~4 MW of AI capacity (expected complete by calendar Q1 2027). Subsequent to the quarter the company announced a contract extension and a new customer agreement, saying this puts it on track for $1 billion in annualized run-rate revenue by calendar Q3 2027, and it received $328.2 million in aggregate prepayments under existing contracts.